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Mutations in rhodopsin, the light-sensitive protein of rod cells, are the most common cause of autosomal dom-
inant retinitis pigmentosa (ADRP). Many rod opsin mutations, such as P23H, lead to misfolding of rod opsin with
detrimental effects on photoreceptor function and viability. Misfolded P23H rod opsin and other mutations in the
intradiscal domain are characterized by the formation of an incorrect disulphide bond between C185 and C187,
as opposed to the correct and highly conserved C110–C187 disulphide bond. Therefore, we tested the hypoth-
esis that incorrect disulphide bond formation might be a factor that affects the biogenesis of rod opsin by study-
ing wild-type (WT) or P23H rod opsin in combination with amino acid substitutions that prevent the formation of
incorrect disulphide bonds involving C185. These mutants had altered traffic dynamics, suggesting a require-
ment for regulation of disulphide bond formation/reduction during rod opsin biogenesis. Here, we show that
the BiP co-chaperone and reductase protein ERdj5 (DNAJC10) regulates this process. ERdj5 overexpression
promoted the degradation, improved the endoplasmic reticulum mobility and prevented the aggregation of
P23H rod opsin. ERdj5 reduction by shRNA delayed rod opsin degradation and promoted aggregation. The re-
ductaseandco-chaperoneactivityofERdj5werebothrequired for theseeffectsonP23Hrodopsin.Furthermore,
mutations in these functional domains acted as dominant negatives that affected WT rod opsin biogenesis.
Collectively, these data identify ERdj5 as a member of the proteostasis network that regulates rod opsin biogen-
esis and supports a role for disulphide bond formation/reduction in rod opsin biogenesis and disease.
INTRODUCTION
Rhodopsin, the light-absorbing photopigment of rod cells, is the
archetypalG-protein-coupled receptor (GPCR) and is composed
of the apoprotein rod opsin and the covalently linked 11-cis
retinal chromophore, an analogue of vitamin A. The apoprotein
rod opsin is synthesized in the rough endoplasmic reticulum
(ER) membrane in the inner segments of rod photoreceptor
cells before being trafficked to the rod outer segment photosen-
sory cilia. Rhodopsin undergoes several post-translationmodifi-
cations during its biogenesis, including the formation of a
disulphide bondbetweenC110andC187 residues in the intradis-
cal domain (1–4). This disulphide bond is highly conserved
among other GPCRs such as the b2 adrenergic and M1 muscar-
inic receptors (5,6).
Mutations in rod opsin cause the neurodegenerative disease
retinitis pigmentosa (RP) that leads to blindness as a result of
photoreceptor cell death. The first mutation associated with
RP, a proline-to-histidine substitution in codon 23 (P23H), was
reported in 1990 and found to cause autosomal dominant RP
[autosomal dominant retinitis pigmentosa (ADRP)] (7). Since
then, over 200 rhodopsin point mutations have been described,
which account for 25% of all ADRP cases (RetNet: http://
www.sph.uth.tmc/edu/Retnet/). The P23H mutation, however,
is the most common mutation in North America and the most
studied. The P23 residue is found in the intradiscal domain of
rhodopsin. Mutations in this domain have been found to cause
partial (e.g. P23H and D190A) or total misfolding (e.g.
G188R, C110F, C110Y and C187Y), with limited ability to
∗Towhom correspondence should be addressed at: UCL Institute of Ophthalmology, 11–43 Bath Street, London, EC1V 9EL, UK. Tel: +44 2076086944;
Fax: +44 2076086892; Email: michael.cheetham@ucl.ac.uk
# The Author 2014. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/),
which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Human Molecular Genetics, 2014, Vol. 23, No. 24 6594–6606
doi:10.1093/hmg/ddu385
Advance Access published on July 23, 2014
bind11-cis retinalandformafunctional, stablephotopigment (8,9)
and have been classified as Class II mutations (10). Studies of
ADRP-associated mutations, as well as designed mutations in
the intradiscal domain, have shown the presence of a non-native
disulphide bond between C185 and C187 residues (3,8,11–13).
While initially this incorrect disulphide bond was thought to be
the cause of misfolding in these mutants, later it was suggested
that it traps misfolded forms of rod opsin and is not the sole or
direct cause of rod opsin misfolding (3).
Rod opsin folding-defective polypeptides are not allowed to
traffic through the secretory system, for example, heterologous
expression of P23H rod opsin showed that it is retained in the
ER (14,15). ER-retained P23H rod opsin is subject to retrotran-
slocation andER-associated degradation (ERAD), a process that
requires the reduction of any interchain or intrachain disulphide
bonds (16). Upon failure of ERAD, P23H rod opsin can spontan-
eously aggregate and form microscopically visible inclusion
bodies (17,18). In the photoreceptors of homozygous P23H
knock-in mice, the vast majority of P23H rod opsin is degraded;
however, a small amount escapes the ER and traffics to ciliary
protrusions where it forms elongated discs (19,20). Rod opsin
misfolding can stimulate the unfolded protein response (21),
which is a coordinated stress response that reduces translation,
induces expression of molecular chaperones and stimulates
ERAD to recover from protein misfolding stress in the ER.
Previous studies have shown that molecular chaperones are
important for rod opsin biogenesis and photoreceptor function
(22,23), whereas pharmacological manipulation of their activity
can alleviate the toxic effects of misfolded and mutant rod opsin
(24–26).
Someof the factors that facilitate normal rodopsin folding and
the quality control of mutant rod opsin have been discovered.
The ER degradation-enhancing a-mannosidase-like 1 (EDEM1)
and valosin-containing protein (VCP/p97) have been found to
facilitate the degradation of P23H rod opsin (27,28). Calnexin
(Cnx) overexpression can improve the folding of P23H rod
opsin in the presence of 11-cis retinal (29). However, loss of its
activity revealed no requirement for Cnx in P23H rod opsin
ERAD or the biogenesis of normal rod opsin, unlike Drosophila
rhodopsin Rh1 (30–32). Additionally, the ER Hsp70, BiP
(HSPA5), was shown to be important in preventing rod opsin
aggregation in the ER, suggesting that BiP is a critical factor in
the biogenesis and quality control of normal and mutant rod
opsin (33) and its overexpression improves photoreceptor survival
in animalmodelsofP23HRP(34).The requirementof theATPase
activity of BiP for rod opsin biogenesis (33) suggested that an ER
DnaJ protein might also be involved in rod opsin biogenesis.
ERdj5 (also known as DNAJC10 or J-containing PDI-like
protein—JPDI) is the fifthmember of theERdj family ofERpro-
teins. It has a unique structure owing to the combination of a J
domain, which regulates the interaction with BiP, six
thioredoxin-like (Trx) domains (four of which are active reduc-
tases and contain CXXC motifs) and a KDEL tetrapeptide,
which mediates ER retention, within the same structure
(35–38). ERdj5 has been found to be part of two distinct
ERAD pathways that exist for the glycosylated and non-
glycosylated misfolded proteins. This is due to its ability to
act as a reductase that catalyses the reduction of disulphide
bonds of proteins that are targeted for degradation, to act as a
co-chaperone for BiP and to bind to EDEM1 (35–40). Apart
from an ERAD component, ERdj5 has been recently shown to
be required for the folding and secretion of the low-density lipo-
protein receptor (LDLR) highlighting the diversity of its bio-
logical functions (41).
Taking into consideration the relationship of ERdj5 with BiP
and EDEM1, which are both important for rod opsin biogenesis
and the potential requirement for reduction of the non-native
C185–C187 disulphide bond upon rod opsin misfolding, we
investigated the role of ERdj5 in rod opsin biogenesis. Here,
we show that correct disulphide bond formation/reduction is
an important step in rod opsin biogenesis and quality control
that is regulated by ERdj5. Importantly, we identify ERdj5 as
member of rod opsin proteostasis network that promotes the deg-
radation and prevents the aggregation of P23H rod opsin while
facilitating the normal processing of wild-type (WT) rod opsin.
RESULTS
Disulphide bond formation/reduction regulates
rod opsin biogenesis
To investigate the hypothesis that a non-native C185–C187 di-
sulphide bond might affect rod opsin biogenesis, the C185
residue was substituted to alanine (C185A) or serine (C185S)
onWT (Rho-GFP) and P23H (Rho(P23H)-GFP) rod opsin con-
structs tagged at the C-terminus with GFP (17). These substitu-
tions were made in order to eliminate the possibility of the
C185–C187 disulphide bond formation and investigate this
effect on WT rod opsin, as well as in combination with the
P23H mutation. The C185S, C185A and P23H-C185A
mutants have been studied in vitro for their ability to bind to
11-cis retinal (1,3); however, their traffic, mobility in the ER
and the combination of P23H with C185S substitution have
not been described before.
SK-N-SH cells were transfected with Rho-GFP, Rho(C185A)-
GFP, Rho(C185S)-GFP, Rho(P23H)-GFP, Rho(P23H;C185A)-
GFP or Rho(P23H;C185S)-GFP (Fig. 1). In order to determine
empirically the different rod opsin species, cell lysates were
digested with the enzymes endoglycosidase H (EndoH) and
peptide N-glycosidase (PNGase F) before blotting and probing
with a GFP antibody. All WT rod opsin constructs migrated as a
major smear of polypeptides between 55 and 90 kDa and
showed the same resistance on EndoH digestion and sensitivity
to PNGase F digestion (Fig. 1B; Supplementary Material,
Fig. S1A). This agrees with previous reports on indistinguishable
glycosylation and expression pattern betweenWTandC185Aand
C185S mutants (1,3).
Additionally, all Rho(P23H)-GFP proteins migrated as
three distinctive polypeptides ranging from 40 to 70 kDa.
Rho(P23H)-GFP expressed at slightly lower levels compared
with Rho(P23H;C185A)-GFP and Rho(P23H;C185S)-GFP
(Fig. 1D). The 55 kDa polypeptide corresponded to ER-resi-
dent rod opsin as it was sensitive to EndoH digestion and was
enhanced in the double mutants (Supplementary Material,
Fig. S1B). Incubation of all the mutants with both PNGase
F and EndoH enhanced the formation of high-molecular-weight
species on the top of the gel. Previously, it has been shown
that the additionofGFP-tag in rodopsin increases the rate ofmis-
folding and inclusion formation compared with untagged rod
opsin (17,42).
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Live imaging was performed in order to compare the ER dif-
fusional mobility of these constructs by fluorescence recovery
after photobleaching (FRAP) as previously described (33)
(Fig. 1A and C); however, it was not possible to perform
FRAP in Rho(C185A)-GFP- and Rho(C185S)-GFP-expressing
cells because they trafficked more efficiently to the plasma
Figure 1. Prevention of the incorrect C185–C187 disulphide bond affects P23H rod opsin dynamics. SK-N-SH cells were transfected with either (A, B) Rho-GFP,
Rho(C185A)-GFP and Rho(C185S)-GFP or (C–F) Rho(P23H)-GFP, Rho(P23H;C185A)-GFP and Rho(P23H;C185S)-GFP. (A) Representative live-cell images of
Rho-GFP,Rho(C185A)-GFP, Rho(C185S)-GFP andRho-GFP incubated for 15 minwith 3 mMDTT24 h after transfection. Scale bar: 10 mm. (B,D)Western blot of
cell lysates showingRho-GFP (B) andRho(P23H)-GFP (D) probedwith an antibody against GFP. The position of themolecular weightmarkers, in kDa, is shown on
the left. GAPDHwas used as a loading control. (C) Representative live-cell images of Rho(P23H)-GFP, Rho(P23H;C185A)-GFP and Rho(P23H;C185S)-GFP and
Rho(P23H)-GFP incubated for 15 min with 3 mM DTT 24 h after transfection. Scale bar: 10 mm. (E) Graphical representation of fluorescence recovery after photo-
bleach for Rho(P23H)-GFP (black circles), Rho(P23H;C185S)-GFP (grey triangles) and Rho(P23H;C185A)-GFP (white squares). Fluorescence intensities for the
2 × 2-mmareawere normalized to pre-bleach levels at 100%. Error bars represent standard error, n ≥ 12. (F) Graphical representation of recovery after photobleach
for Rho(P23H)-GFP (black circles), Rho(P23H;C185S)-GFP (grey triangles) and Rho(P23H;C185A)-GFP (white squares) in the presence of DTT, as indicated.
Fluorescence intensities for the 2 × 2-mm area were normalized to pre-bleach levels at 100%. Error bars represent standard error, n ≥ 12.
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membrane, compared with Rho-GFP, and there was no discern-
ible GFP fluorescence in the ER (Fig. 1A). The same effect was
observed with Rho-GFP after 15-min incubation with the
reducing agent dithiothreitol (DTT), which reduces disulphide
bonds and inhibits their formation (43,44) (Fig. 1A). Overall
these results suggest that C185A and C185S substitutions do
not have a detrimental effect on the folding and maturation of
Rho-GFP in the ER. In contrast, prevention of the non-native di-
sulphide bond is likely to lead to a faster trafficking of Rho-GFP
to the plasma membrane, suggesting that formation of an incor-
rect disulphide bond might limit the folding rate for WT rod
opsin.
Live imaging of the mutant proteins showed that similar
to Rho(P23H)-GFP, both double mutants were retained in the
ER and no clear plasma membrane localization was observed
(Fig. 1C). FRAP was performed in low-expressing, large-inclu-
sion-free cells and showed that the recovery of Rho(P23H)-GFP
was 65% of pre-bleached levels, similar to previous studies of
Rho(P23H)-GFP mobility (33) (Fig. 1E). In contrast, both double
mutants were more mobile and showed similar levels of recovery
that reached 75% of pre-bleached levels (Fig. 1E). This sug-
gested that both double mutants were more soluble in the ER pos-
sibly as a result of the prevention of abnormal disulphide bond
formation.
Within 15-min incubation of the cells with 3 mM DTT,
Rho(P23H)-GFP showed 20% increase in its recovery, which
reached 85% recovery of the pre-bleached levels. Interestingly,
treatment with DTT led to a 4% increase in the recovery of
Rho(P23H;C185A)-GFP and a 7% increase in Rho(P23H;C185S)-
GFP(Fig.1F).Asthesemutantscouldnotformalternative intrachain
disulphide bonds, it was anticipated that they would be resistant to
DTT treatment. Although this increase was much lower than the
one observed in Rho(P23H)-GFP, the effect of DTT might reflect
a reduction of potential interchain bonds as a result of C185A or
C185S substitutions. Overall, these results suggest that both inter-
chain and intrachain disulphide bonds can slow rod opsin mobility
in the ER.
ERdj5 binds to WT rod opsin and dysfunctional
ERdj5 affects opsin traffic
The effect of C185 substitutions on the trafficking of WT rod
opsin and the ER mobility of P23H suggested a requirement
for regulation of disulphide bond formation/reduction and sub-
sequently that a reductase protein might be important for rod
opsin biogenesis. ERdj5 is an excellent candidate reductase
because it links together BiP and EDEM1, two chaperones that
have already been shown to affect rod opsin (27,33). To investi-
gate a potential role of ERdj5 in WT rod opsin trafficking,
SK-N-SH cells were co-transfected with Rho-GFP alone or
co-transfected with Rho-GFP and either ERdj5, the reductase
mutant ERdj5-SS or the J domain mutant ERdj5-H63Q
(Fig. 2A). All the ERdj5 constructs contained a haemagglutinin
(HA) tag at the position before theC-terminal KDEL (37,39,45).
When ERdj5 was co-expressed with Rho-GFP, ERdj5 was loca-
lized in the ER and did not strongly co-localize with Rho-GFP,
which was mainly present at the plasma membrane with only a
small amount visible in the ER corresponding to normal synthe-
sis. ERdj5 displayed a reticular pattern,which is characteristic of
ER-resident proteins and is consistent with previous studies in
HeLa, COS-7 and SH-SY5Y cells (35,37,46). Co-expression
of Rho-GFP with the ERdj5-SS, where all cysteine residues in
the four CXXC motifs of ERdj5 were substituted to serine
Figure 2. ERdj5 interacts withWT rod opsin and ERdj5 reductase and J domain
mutants affect its traffic. (A) SK-N-SH cells were transfected with Rho-GFP
(green) alone (no ERdj5-HA) or co-transfected at 1 : 1 ratio with ERdj5-HA,
ERdj5-SS-HAorERdj5-H63Q-HA, as indicated.Cellswere fixed and immunos-
tained with an antibody against HA for detection of ERdj5 localization (red-
middle panel). Arrows highlight ER retention of Rho-GFP. Scale bar: 10 mm.
(B–C) SK-N-SH cells were transfected with WT rod opsin (Rho) alone
(control-C) or co-transfected with Rho and ERdj5-HA or ERdj5-SS-HA or
ERdj5-H63Q-HA. Twenty-four hours post-transfection, cell lysates were incu-
bated for 2 h with 1D4 antibody against rod opsin (IP: 1D4) or control IgG (IP:
IgG), and immunoprecipitated material was blotted with an antibody against
HA for detection of ERdj5. Input loadingwas 12.5%of IP loading. Arrows high-
light the ERdj5 immunoreactive band. Asterisks highlight non-specific immu-
noreactive bands. The position of molecular weight markers, in kDa, is
highlighted on the left.
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(37,45), showed that in some cells Rho-GFP trafficked to the
plasma membrane, whereas in others it was retained in the ER
and co-localized with ERdj5-SS forming a perinuclear ring-like
structure (Fig. 2A).Moreover, theH63Q substitution of theHPD
motif within the J domain of ERdj5, which prevents binding to
BiP (38,39), also caused ER retention of WT opsin and
co-localization with ERdj5-H63Q in the ER (Fig. 2A). Thus,
loss of ERdj5’s ability to reduce disulphide bonds or to bind to
BiP reduced the traffic ofWT rod opsin to the plasmamembrane
by causing its retention in the ER.
The requirement of functional ERdj5 for rod opsin traffic sug-
gested that ERdj5 might form a complex with WT rod opsin.
To investigate this hypothesis, SK-N-SHcellswere co-transfected
withuntaggedWTrodopsin (Rho) andERdj5-HA,ERdj5-SS-HA
or ERdj5-H63Q-HA. Cell lysates were co-immunoprecipitated
with 1D4 antibody against rod opsin and blotted with an antibody
for HA (Fig. 2B, C). ERdj5 was co-immunoprecipitated withWT
rodopsin; however, the interactionwas strongerwith theERdj5-SS
and ERdj5-H63Q mutants. No ERdj5 immunoreactivity was
detected with the non-specific immunoglobulin G (IgG) pull
down (Fig. 2B, C). These results suggest that ERdj5 forms
a complex with WT rod opsin and that loss of the reductase
activity of ERdj5 or loss of binding to BiP results in a stronger
or prolonged association of ERdj5 with WT rod opsin.
ERdj5 binds to P23H rod opsin and promotes its degradation
ERdj5 can accelerate ERAD of both glycosylated and non-
glycosylated misfolded proteins (35,36,38–40). To investigate a
possible role of ERdj5 in P23H rod opsin degradation and traffick-
ing, ERdj5 and the mutants ERdj5-SS-HA and ERdj5-H63Q-HA
were co-transfected with Rho(P23H)-GFP (Fig. 3A). The image
acquisition settings used for immunofluorescence and confocal
microscopy were kept the same for all conditions in order to
monitor the expression level of Rho(P23H)-GFP and correlate a
decrease in fluorescence with a reduction in Rho(P23H)-GFP ex-
pression. Overexpression of ERdj5 reduced the fluorescence level
of Rho(P23H)-GFP suggesting that P23H degradation might be
increased. Imaging at increased intensity levels revealed that the
remaining Rho(P23H)-GFP was still retained within the ER
(Fig. 3A inset). In contrast, overexpression of ERdj5-SS-HA or
ERdj5-H63Q-HA resulted in increased levels of Rho(P23H)-GFP
andco-localizationwithmutantERdj5 in theERwithenhanced in-
clusion formation (Fig. 3A). These results suggest a role of ERdj5
in the degradation of P23H rod opsin, which is blocked in
the absence of the reductase activity of ERdj5 or when ERdj5
cannot bind BiP. Moreover, ERdj5 was often recruited to
Rho(P23H)-GFP inclusions (77% incidence), whereas ERdj5-SS
and ERdj5-H63Q always co-localized with Rho(P23H)-GFP in
inclusions (100% incidence) (Supplementary Material, Fig. S2).
The presence ofERdj5 inP23H inclusions suggested that ERdj5
might recognize P23H as a misfolded conformer and attempt to
promote its degradation, a process that might be blocked by the
SS and H63Q mutations and lead to stronger association of P23H
with the ERdj5 mutants. To investigate whether ERdj5 forms a
complex with P23H, co-immunoprecipitation was performed in
cells co-transfected with Rho(P23H) and ERdj5 or Rho(P23H)
with the mutants ERdj5-SS and ERdj5-H63Q (Fig. 3B, C).
ERdj5-SS and ERdj5-H63Q mutants co-immunoprecipitated
with P23H rod opsin but not at higher levels than ERdj5, as
Figure 3. ERdj5 reductase and J domain mutants cause accumulation of P23H
rod opsin. (A) SK-N-SH cells were transfected with Rho(P23H)-GFP (green)
alone (no ERdj5-HA) or co-transfected at 1 : 1 ratio with ERdj5-HA,
ERdj5-SS-HA or ERdj5-H63Q-HA and immunostained with an antibody
against HA for detection of ERdj5 localization (red-middle panel). Cells were
analysed by confocal microscopy keeping the same scanning intensity levels
between all conditions. The inset boxes highlight the localization of
Rho(P23H)-GFP after increasing the detection sensitivity. Scale bar: 10 mm.
(B–C) SK-N-SH cells were transfected with Rho(P23H) alone (control-C) or
co-transfected with ERdj5-HA, ERdj5-SS-HA or ERdj5-H63Q-HA. (D) Com-
parison of ERdj5 co-immunoprecipitation with Rho or Rho(P23H), as indicated.
Twenty-fourhourspost-transfection, cell lysateswere incubated for 2 hwith1D4
antibody against rod opsin (IP: 1D4) or control IgG (IP: IgG), and immunopreci-
pitatedmaterial was blottedwith an antibody against HA for detection of ERdj5.
Input loadingwas 12.5%of IP loading.Arrows highlight ERdj5 immunoreactive
band. Asterisks highlight non-specific immunoreactive bands. The position of
molecular weight markers, in kDa, is highlighted on the left.
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expected, and as observed with WT rod opsin (Fig. 2B, C). We
believe that this difference is potentially due to insolubility of the
complex between P23H and ERdj5 mutants. A similar effect was
also observed with an ATPase-mutant of BiP(T37G) and P23H
(33). Finally, to address whether ERdj5 binds stronger to WT or
P23H rod opsin, co-immunoprecipitation was performed in cells
co-expressing WT or P23H with ERdj5, which showed that there
was greater recovery of ERdj5 with P23H compared with WT
rod opsin, indicating preferential binding to the mutant rod opsin
(Fig. 3D).
To confirm that ERdj5mediates P23Hdegradation, cells were
co-transfected with untagged P23H rod opsin (Rho(P23H)) and
ERdj5, ERdj5-SS or ERdj5-H63Q. Prior to cell lysis, cells were
either left untreated or treated for up to 4 h with cycloheximide
(CHX), which inhibits protein synthesis and can be used as a
tool to investigate differences in half-life and degradation of
proteins (Fig. 4). Protein quantification showed that the steady
state Rho(P23H) levels were reduced in the presence of ERdj5,
whereas they were increased in the presence of ERdj5-SS and
ERdj5-H63Q mutants (Fig. 4A, B). Treatment with CHX (4 h)
resulted in a 40% reduction of Rho(P23H) levels and a significant
enhancement of degradation [60% reduction of Rho(P23H)
levels] in the presence of ERdj5 (Fig. 4A, C). Interestingly, the
presence of ERdj5-SS or ERdj5-H63Q did not lead to a further
reduction of Rho(P23H) levels, as they did not promote
Rho(P23H) degradation.When the levels of P23Hwere normal-
ized to the control (0 h, CHX treatment) to assess the rate of
degradation (Fig. 4D), the presence of ERdj5 led to a significant
decrease in the amount of Rho(P23H), a 30% drop after 2 h and
over 50% after 4 h of CHX treatment (Fig. 4D). Overall, these
results suggest that ERdj5 can stimulate the degradation of
P23H rod opsin, a process that requires both the reductase
activity of ERdj5 and its ability to bind to BiP.
ERdj5 affects WT and P23H mobility in the ER
The ER retention of Rho-GFP after co-expression with ERdj5-SS
suggested that loss of the reductase activity of ERdj5 might
enhance aggregation and reduce Rho-GFP mobility in the ER. In
order to investigate this, Rho-GFP was either co-expressed with
ERdj5 or ERdj5-SS and FRAP analysis was performed
(Fig. 5A). Rho-GFP showed 80% recovery of the pre-bleached
levels, as previously described (33) and its ER mobility was not
altered by ERdj5 overexpression. Conversely, co-expression
with the reductase mutant reduced Rho-GFP mobility by 20%
as Rho-GFP only recovered 60% of the pre-bleached level
(Fig. 5A). This result suggests a requirement for ERdj5 reductase
activity to maintain WT rod opsin solubility in the ER.
Moreover, the involvement of ERdj5 in the degradation of
P23H rod opsin suggested that this might be accompanied by a
reduction in P23H aggregation in the ER. Therefore, FRAP ana-
lysis was performed in Rho(P23H)-GFP cells overexpressing
ERdj5 or ERdj5-SS (Fig. 5B). The Rho(P23H)-GFP control
cells exhibited 60–65% recovery of the pre-bleached levels,
which was reduced by 10% after co-expression with the
mutant ERdj5-SS. Interestingly, upon ERdj5 overexpression,
P23H rod opsin mobility was accelerated and its recovery
reached 80% of the pre-bleached values, similar to the recovery
rate of Rho-GFP and to that observed in P23H after overexpres-
sion of BiP (33). Unlike WT rod opsin, treatment with DTT did
not affect the localization or traffic of P23H. Nevertheless, DTT
improved P23H mobility with similar efficiency to ERdj5, sug-
gesting that this improvement involves the reductase activity of
ERdj5 (Fig. 5B).
To confirm that the above-mentioned alterations in rod opsin
mobility were specific to rod opsin and not due to global alter-
ation in the ER membrane fluidity after ERdj5 manipulation or
DTT treatment, the same conditions were repeated in cells
expressing the ER-associated protein YFP-HSJ1b(274-324)
Figure 4. ERdj5 enhances the degradation of P23H rod opsin. SK-N-SH cells
were either transfected with untagged P23H rod opsin (Rho(P23H)) or
co-transfected at 1 : 1 ratio with Rho(P23H) and ERdj5, ERdj5-SS or
ERdj5-H63Q as indicated. Prior to lysis, cells were left untreated or treated
with 50 mg/ml CHX for the indicative time (h). Ten micrograms of soluble
protein was resolved and probed with the 1D4 antibody against rod opsin.
(A) Western blot of Rho(P23H) expression following transfection with ERdj5,
ERdj5-SS or ERdj5-H63Q and CHX treatment at 0 and 4 h. b-tubulin was
used as a loading control. The position of molecular weight markers, in kDa, is
highlighted on the left. (B) Graphical representation of the steady state levels
of Rho(P23H) in the presence of ERdj5, ERdj5-SS or ERdj5-H63Q. The levels
are expressed as a percentage ofRho(P23H) at time 0. Error bars represent stand-
ard error, n . 4. (C) Graphical representation of the percentage of Rho(P23H)
remaining levels in the presence of ERdj5, ERdj5-SS or ERdj5-H63Q following
4 h treatment with CHX. Error bars represent standard error, n. 4.∗P, 0.05,
student’s t-test. (D) Degradation of Rho(P23H) in the absence or presence of
ERdj5 after 0-, 2- and 4 h treatment with CHX. The levels were normalized to
100% at time 0. Error bars represent standard error, n . 4.∗P, 0.05, student’s
t-test.
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(SupplementaryMaterial, Fig. S3).As previously observed (33),
YFP-HSJ1b(274-324) showed a rapid recovery reaching 85%
of the pre-bleached levels. Its recovery and ER localization
remained unaltered after ERdj5 or ERdj5-SS overexpression
as well as after incubation with DTT, suggesting that the above-
mentioned observations were specific to rod opsin (Supplemen-
tary Material, Fig. S3). In conclusion, these results highlight a
role of the reductase activity of ERdj5 in improving rod opsin
solubility in the ER, preventing its aggregation and promoting
its degradation.
Silencing of ERdj5 leads to accumulation of rod opsin
in the ER
To investigate the effect of endogenous ERdj5 in rod opsin bio-
genesis, a short hairpinRNA (shRNA)was produced and used to
silence the expression of human ERdj5 via RNA interference.
Initially, the shERdj5 was tested in SK-N-SH cells and found
to be effective in reducing ERdj5 RNA and protein levels up to
90% (Supplementary Material, Fig. S4). Co-transfection of
Rho-GFP and increasing amounts of shERdj5 led to retention
of Rho-GFP in the ER (Fig. 6A). Reduction of ERdj5 led to a
global increase of WT Rho levels and especially the 36-kDa
species, which corresponds to the EndoH-sensitive glycoform
of WT rod opsin that has not trafficked beyond the ER
(Fig. 6B) (33). Additionally, silencing of ERdj5 led to increased
levels of Rho(P23H)-GFP in the ER and an increase in the
number of Rho(P23H)-GFP inclusions compared with
Rho(P23H)-GFP control cells (Fig. 6C), as well as a global
increase of the 28-, 36- and 45–60-kDa species of
Rho(P23H), which correspond to an N-terminal truncated
protein, the EndoH-sensitive glycoform and dimer, respectively
(Fig. 6D) (17,29,47). These findings suggest that silencing of
ERdj5 can affect the traffic of WT rod opsin and can increase
accumulation of P23H in the ER, thus making it more prone to
aggregation.
DISCUSSION
The ER is a compartment that is critical for protein folding, as-
sembly and disulphide bond formation. However, a fraction of
newly synthesized proteins never reach the correct native state
and are subjected to retrotranslocation from the ER and ERAD
(48). Efficient retrotranslocation of misfolded proteins requires
reduction of disulphide bonds andprotection of reduced cysteine
residues fromfurther reactionprior todislocation.The formation
of other unwanted intrachain or interchain disulphide bonds
must also be avoided (16). Such a requirement is likely to be im-
portant for retrotranslocation ofmisfolded rodopsin, as it is char-
acterized by an non-native disulphide bond between C185 and
C187 as opposed to the native disulphide bond between C110
and C187 (1,2). The data presented here suggest that the
co-chaperone and reductase ERdj5 promotes the degradation
and prevents the aggregation of P23H rod opsin and is also
involved in the processing of WT rod opsin.
ERdj5 is an important component of the ER quality control
machinery. It is the largest of the PDI family of proteins and
the only one to contain a J domain and multiple active thiore-
doxin domains within the same structure (35–38). These
unique structural characteristics allow ERdj5 to catalyse the re-
duction of disulphide bonds of misfolded non-glycoproteins or
glycoproteins received from EDEM1 and transfer the reduced
proteins toBiP in anATP-dependentmanner (36,40). Both func-
tions seem to play a role in the normal processing of WT rod
opsin as co-expression with ERdj5-SS and ERdj5-H63Q
mutants that block its reductase and its co-chaperone activity, re-
spectively, resulted in retentionand accumulation of a fractionof
WT rod opsin in the ER. The same effect on WT rod opsin was
observed after shERdj5-mediated silencing of ERdj5. Addition-
ally,whileoverexpressionof thewild-type formofERdj5didnot
promote P23H folding as seen with EDEM1 (27), it accelerated
Figure 5.ERdj5 affects rod opsinmobility in the ER. SK-N-SH cells were either
transfected with Rho-GFP alone or co-transfected with Rho-GFP and ERdj5
(1 : 2 ratio) or ERdj5-SS (1 : 1 ratio), and 24 h later, live-cell imaging was per-
formed. (A) Graphical representation of recovery after photobleach for
Rho-GFP (white triangles) and Rho-GFP in the presence of ERdj5 (grey dia-
monds) or ERdj5-SS (black triangles). Fluorescence intensities for the 2 ×
2-mm area were normalized to pre-bleach levels at 100%. Error bars represent
standard error, n ≥ 12. (B) Graphical representation of recovery after photo-
bleach for Rho(P23H)-GFP (black circles), Rho(P23H)-GFP treated with 3 mM
DTT (grey triangles) and Rho(P23H)-GFP in the presence of ERdj5 (black
diamonds) or ERdj5-SS (white squares). Fluorescence intensities for the 2 ×
2-mm area were normalized to pre-bleach levels at 100%. Error bars represent
standard error, n ≥ 12.
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P23H degradation. P23H degradation was blocked by ERdj5
mutants, and ERdj5 knockdown led to a further accumulation
of P23H in the ER. This is consistent with another study,
which showed thatERdj4 andERdj5 accelerated thedegradation
of the non-glycosylated misfolded surfactant protein C (SP-C),
and the effect was reversed in the presence of ERdj4-H54Q
and ERdj5-H63Q mutants or by downregulation of ERdj4 and
ERdj5 (39). Another study reported that overexpression of
ERdj5 accelerated the degradation of two glycoproteins, the
null Hong Kong (NHK) variant of human a-1 antitrypsin and
the J chain of mouse immunoglobulin M (38). For both these
client proteins, degradation was blocked in the presence of
ERdj5-SS and ERdj5-H63Q mutants suggesting that both func-
tions are required, because ERdj5-H63Q that retains the reduc-
tase activity failed to accelerate ERAD (38).
In the present study, these ERdj5 mutants had the same effect
on blocking the degradation of P23H, implying that both func-
tional domains are required for P23H ERAD. Moreover,
further support for the role of ERdj5 in P23H degradation is
evident from co-localization of ERdj5 and ERdj5 mutants in
P23H inclusions. Previously, it has been shown that other mo-
lecular chaperones can be recruited to P23H inclusions such as
Hsp70, HSJ1a and HSJ1b (17,49). The presence of ERdj5 in
P23H inclusions as well as the effect of ERdj5 downregulation
or functional inhibition suggested that ERdj5 might form a
complex with rod opsin. Co-immunoprecipitation studies
showed that ERdj5 binds to WT rod opsin suggesting that
ERdj5 has a role in normal rod opsin biogenesis. This binding
was not dependent on the presence of active CXXC motifs or a
functional J domain as ERdj5-SS and ERdj5-H63Q mutants
also co-immunoprecipitated with WT rod opsin. The stronger
association of WT rod opsin with the ERdj5-SS mutant could
indicate prolonged binding owing to its lack of ability to act as
a reductase. Additionally, prolonged binding of WT rod opsin
to theERdj5-H63Qcould suggest lack of ability to facilitate sub-
strate release without BiP binding and potential client protein
handover. These results for WT rod opsin are consistent with
the ER retention observed upon co-expression of the ERdj5
mutants with the LDLR (41). Moreover, ERdj5 bound preferen-
tially to mutant P23H rod opsin; however, this binding was not
enhanced by the ERdj5-SS and ERdj5-H63Q mutations. This
was unexpected, as it is anticipated that ERdj5 would bind
P23H to promote ERAD and release would require reduction
of disulphide bonds and BiP binding. We believe that the
failure to detect stronger bindingmight be due to the insolubility
of these complexes, as the same effect was observed with an
ATPase-mutant of BiP (33).
Further support for this hypothesis is provided by the reduced
mobility of Rho(P23H)-GFP in the ER after co-expression with
the reductase mutant. Importantly, the converse effect on P23H
mobility was observed after ERdj5 overexpression, by preven-
tion of the non-native C185–C187 disulphide bond or after
short incubation with the reducing agent DTT. A similar effect
for DTT was reported with the misfolded vesicular stomatitis
virus G (VSVG) (44,50). DTT had some effect on
Rho(P23H;C185A)-GFP and Rho(P23H;C185S)-GFP mobil-
ity, despite thesemutants not being able to formalternative intra-
chain disulphide bonds. Previously, DTT treatment has been
shown to accelerate the ER mobility of Galt-GFP, which does
not contain any intrachain disulphide bonds, after incubation
with brefeldin A (BFA), which blocks exit of proteins in the
ER (50). The improvement of Rho(P23H;C185A)-GFP and
Figure 6. shRNA for ERdj5 results in accumulation of rod opsin. SK-N-SH cells were transfected with rod opsin and empty vector or rod opsin and increasingmolar
plasmidequivalents (1 : 1, 1 : 2) (arrows)of shERdj5 (+ shERdj5), as indicated. (A)Cells expressingRho-GFPwerefixedandanalysedbyconfocalmicroscopy.Scale
bar: 10 mm. (B) Cell lysates (10 mg) of Rho in the absence or presence of shERdj5 were resolved and western blotted with 1D4 against rod opsin and GAPDH as a
loading control. The position of the molecular weight markers, in kDa, is highlighted on the left. (C) Cells expressing Rho(P23H)-GFP were fixed and analysed by
confocal microscopy. Arrows highlight Rho(P23H)-GFP inclusions. Scale bar: 10 mm. (D) Cell lysates (10 mg) of Rho(P23H) in the absence or presence of shERdj5
were resolved andblottedwith 1D4against rodopsin andGAPDHas a loading control. The positionof themolecularweightmarkers, in kDa, is highlightedon the left.
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Rho(P23H;C185S)-GFP mobility after DTT treatment might
reflect a general change in the ER membrane viscosity after re-
duction of disulphide bonds. However, DTT treatment did not
affect themobility of the ER-associated protein HSJ1b, suggest-
ing no gross changes in membrane fluidity. Therefore, DTT
might have a more specific effect on proteins that are no longer
associated in dynamic crosslinked aggregates or proteins that
form incorrect interchain bonds (50,51). These findings
suggest that non-native inter- and intra-chain disulphide bonds
are a factor for P23H immobilization in the ER and that the re-
ductase activity ofERdj5 is important inmaintainingP23H solu-
bility in the ER.
Interestingly, while overexpression of ERdj5 had no effect on
Rho-GFP mobility in the ER, co-expression with ERdj5-SS
reduced WT mobility implying a requirement of a fraction of
WTrodopsin for disulphide bond reduction for efficient traffick-
ing. Previous studies have shown that C185A and C185S muta-
tions were able to fold efficiently, bind to 11-cis retinal and
regenerate rhodopsin (1,3). The C185A mutant, however,
which was more extensively characterized, was found to be
less thermally stable than WT rod opsin with slow affinity
rates for 11-cis retinal. The C185A mutation appeared to desta-
bilize the open-pocket conformation of opsin leading to an equi-
librium between correctly folded and denatured states of opsin
(1,3). Therefore, it is possible that the correct disulphide bond
between C110 and C187 residues is formed only in a fraction
of Rho-GFP, which traffics efficiently and quickly to the
plasma membrane, whereas the fraction that forms the C185–
C187 or C110–C185 bond belongs to off-pathway folding
intermediates that limit folding to the native state in the ER.
This might explain the live-cell imaging results in the present
study, which showed faster trafficking of Rho(C185A)-GFP
and Rho(C185S)-GFP mutants to the plasma membrane, as
opposed to Rho-GFP, and similar to the effect of reducing con-
ditions with DTT on Rho-GFP. Additionally, the presence of
the off-pathway folding intermediates in the ER might also
explain why the Rho-GFP mobile fraction does not fully
recover and its levels only reach 80% of the pre-bleached
values.
Therefore, it is likely that ERdj5 prevents WT rod opsin from
forming incorrect intra- or inter-molecularbondswhile it is in the
ER. Its association with rod opsin folding intermediates and its
associationwithBiP could help rod opsin tomaintain its solubil-
ity in the ER until further chaperones and folding factors com-
plete the folding of rod opsin (33). The interaction of ERdj5
with P23H rod opsin also supports the hypothesis that ERdj5,
like ERdj3 and ERdj4, can bind directly to misfolded protein
substrates, thus acting as a chaperone and co-chaperone that
recruits BiP (39,52,53). Previously, it has been proposed that
ERdj5-mediated ERAD requires EDEM1 to function because
inhibition of mannose trimming by kifunensine blocked
ERAD of NHK and immunoglobulin J chains even when
ERdj5 was overexpressed (38). However, it has been shown
that EDEM1 recognition of misfolded substrates does not
require mannose trimming, but instead, this can be mediated
by exposed hydrophobic domains (54). Two lines of evidence
support this hypothesis. Both mannose trimming and glycan
chains were not required for P23H rod opsin degradation or for
P23H-EDEM1 binding (27). More recently, it has been shown
that the degradation of glycoprotein substrates such as NHK
can be mediated via the BiP/ERdj5 pathway, which serves as a
back-up ERAD pathway upon ER stress (40).
Therefore, the data presented here in combination with previ-
ous findings on the role of EDEM1 and BiP on rod opsin (27,33)
suggest the formation of a proteostasis network between BiP,
ERdj5 and EDEM1 that is important for rod opsin biogenesis
and quality control. A previously described model of this net-
work’s potential roles in thequality control ofmisfoldedproteins
(36) has been modified for rod opsin as the client protein and is
illustrated in Figure 7. Rod opsin could fold correctly, acquire
the correct disulphide bond (C110–C187) and traffic through
the secretory pathway to the Golgi and to the plasma membrane
with little or no chaperone assistance. Alternatively, rod opsin
couldmisfoldandaminoacid substitutions, suchas class IImuta-
tions, would increase the potential risk of this occurring. The
misfolded rod opsin could form either incorrect intrachain
(C185–C187 or C110–C185) or interchain disulphide bonds.
In that case, ERdj5 reduces the aberrant disulphide bonds and
rod opsin could either refold to its correct conformation or be
subjected to ERAD via the EDEM1-ERdj5-BiP pathway or the
ERdj5-BiP pathway. Alternatively, EDEM1 may bind mis-
folded rod opsin directly and correct the folding or promote
the degradation of rod opsin. If molecular chaperone-mediated
quality control fails, misfolded rod opsin could accumulate
in the ER leading to rod opsin aggregation in the ER or in the
cytoplasm following retrotranslocation and failed proteasomal
degradation.
Collectively, the data presented here identify ERdj5 as
the third member of a specialized proteostasis network
(BiP-ERdj5-EDEM1) that regulates rod opsin biogenesis, facil-
itates rod opsin quality control and reduces mutant rod opsin ag-
gregation. Manipulation of this network might be a viable
therapy for these currently untreatable forms of blindness.
MATERIALS AND METHODS
Materials
Themousemonoclonal primary antibody 1D4 (1 : 1000) against
rod opsin was a gift from Professor Robert Molday (Department
of Biochemistry and Molecular Biology, University of British
Columbia, Canada). Cycloheximide, DTT, protease inhibitor
cocktail (PIC) and antibodies to HA (H6908) (1 : 1000), to
GFP (G1546) (1 : 1000), to b-tubulin (T8328) (1 : 2000) and to
GAPDH (G8735) (1 : 40 000) were from Sigma (Poole, UK).
Lipofectamine, Plus reagent, goat anti-mouse Alexa Fluor 594
secondary antibody-conjugated IgG (1 : 1000) and protein G
magnetic Dynabeads were purchased from Invitrogen (Paisley,
UK). Endoglycosydase (EndoH) and Peptide N-glycosidase F
(PNGase F) were from New England Biolabs (Herts, UK). The
bicinchonitic acid (BCA) protein assay kit and goat anti-mouse
secondary antibody conjugated to horseradish were from Pierce
(Thermo Scientific Cramlington, UK). The Quikchange II site-
directed mutagenesis kit was from Agilent Technologies (Berk-
shire, UK). The RNeasy Mini Kit and QuantiTect Reverse
Transcription Kit were from Qiagen (Manchester, UK). The
ECL Plus reagent kit was from GE Healthcare (Buckingham-
shire, UK).
6602 Human Molecular Genetics, 2014, Vol. 23, No. 24
Expression construct, site-directed mutagenesis
and shRNA production
Rodopsin constructs, untagged rod opsin in pMT3 (Rho) and rod
opsin-GFP (Rho-GFP), were as described previously (17). The
Rho(C185A)-GFP, Rho(C185S)-GFP, Rho(P23H;C185A)-
GFP, Rho(P23H;C185S)-GFP expression plasmids were gener-
ated by site-directed mutagenesis using either the Rho-GFP or
the Rho(P23H)-GFP construct as template. All constructs were
confirmed by sequencing. ThemERdj5-HA andmERdj5-SS ex-
pression plasmids were as described (39). The hERdj5-HA and
hERdj5-H63Q expression plasmids were a gift from Dr
Weaver (CCMC,Ohio). YFP-HSJ1b(274-324)was as described
previously (33). For shERdj5 production, two sets of oligos
(forward and reverse) were designed based on the GGAGGA-
GAUUGUUUGACUU published siRNA sequence (55). The
sequence of the forward oligo included the siRNA sequence in
sense (5′) and antisense (3′) orientation separated by the
CTCGAG nucleotide-specific loop sequence (hairpin). The
oligos were ordered from MWG Eurofins (Abingdon, UK) and
were cloned to pSUPER vector (OligoEngine, Washington).
The presence of the correct insert within the recombinant
pSUPER vector was confirmed by sequencing using the M13
primer GTAAAACGACGGCCAGT.
Cell culture, transfection and immunofluorescence
SK-N-SH human neuroblastoma cells were maintained, trans-
fected and imaged essentially as previously described (27).
Briefly, cells were seeded on chamber slides at a density of
50 000 cells/well and transfected with 200 ng of total DNA.
Twenty-four hours after transfection, cells were fixed with
ice-cold methanol or 4% paraformaldehyde and permeabilized
with Triton X-100 (0.5%) (Sigma, UK) in phosphate-buffered
saline (PBS) (137 mM sodium chloride, 2.7 mM potassium chlor-
ide, 8.1 mM di-sodium hydrogen phosphate, 1.5 mM potassium
dihydrogen phosphate; OXOID, UK). Non-specific binding was
blocked for 1 h with PBS containing 3% (w/v) bovine serum
albumin (BSA) and 10% (v/v) normal donkey serum. Anti-HA
antibody (1 : 1000) primary antibody in blocking buffer was
added for 1 h followed by washing with PBS, and secondary anti-
body Alexa Fluor 594-conjugated IgG was used at 1 : 1000 in
blocking buffer for 1 h. Cells were washed twice with PBS and
once with DAPI at a concentration of 2 mg/ml in PBS prior to
mounting in fluorescent mounting medium (DAKO, Cambridge-
shire, UK). Fluorescence was observed on a Carl Zeiss LSM 700
confocal laser-scanning microscope for image acquisition.
Images were exported from LSM browser to Adobe Photoshop
for figure preparation and annotation in Adobe Illustrator.
Figure 7. Model of molecular chaperone modulation on rod opsin biogenesis. Left side: rod opsin could fold correctly, acquire the correct disulphide bond
(C110–C187; S-S) and translocate through the secretory pathway. Right side: alternatively, it might misfold and form either an incorrect intrachain (C185–
C187 or C110–C185; S- -S) or interchain disulphide bonds (S- -S). ERdj5 reduces the aberrant disulphide bonds (SH). Rod opsin can either refold to its
correct conformation or be subjected to ERAD via the ERdj5/BiP or EDEM1/ERdj5/BiP pathway. EDEM1 binds to the C-terminus of ERdj5, whereas BiP
binds to the J domain. Upon BiP ATP hydrolysis, rod opsin is dislocated and degraded by the proteasome. Alternatively, EDEM1 may bind misfolded rod
opsin directly and correct the folding or promote the degradation of rod opsin. If molecular chaperones are not recruited, misfolded rod opsin could be retained
in the ER leading to rod opsin aggregation.
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FRAP analysis
SK-N-SH cells were seeded on MatTek (MatTex Corp, MA,
USA) slide dishes at a density of 600 000 cells/dish and after
24 h were transfected with 2000 ng of total DNA. Live
imaging and FRAPwas performed 24 h after transfection as pre-
viously described (33). For the DTT treatment, 3 mM DTT was
administered 15 min prior to live imaging.
SDS–PAGE and western blot
Cellswere lysedwith 1%(w/v) n-Dodecyl-b-D-maltoside (DM)
lysis buffer containing2%(v/v)mammalianPIC, 2%(v/v)mam-
malian phosphatase inhibitor cocktail and 5 mm ethylenedi-
amine tetraacetic acid (EDTA) in PBS. Cell lysates were
centrifuged for 15 min at 12 000×g and at 48C. Protein concen-
tration was measured with the BCA Protein Assay kit (Pierce)
following the manufacturer’s instructions. For the deglycosyla-
tion reactions, 10 mg of total protein in DM soluble cell lysate
was digested with PNGaseF or EndoH for 2 h at 378C. Cell
lysates were diluted in 2× sodium dodecyl sulphate (SDS)
sample loading (10%SDS,20%glycerol, 0.1%(w/v) bromophe-
nol blue, 0.5 M Tris–HCl, pH 6.8, 2.5% (v/v) 2-bmercaptoetha-
nol), to a final concentration of 1×. Samples for rod opsin blot
were not denatured, whereas samples for all the other antibodies
were heated at 958C for 5 min before they resolved by SDS–
polyacrylamide gel electrophoresis (SDS–PAGE) and western
blot. Proteins were transferred to nitrocellulose with 25 mM
Tris, 192 mM glycine, 0.01% SDS (w/v) and 20% (v/v) metha-
nol. To prevent non-specific binding, membranes were
blocked at 48C with 5% (w/v) Marvel Milk in PBS with 0.1%
(v/v) tween and immunodetection with the proteins of interest
was carried out using the primary and secondary antibodies
described in Materials section. Proteins were detected using
ECL Plus reagent (GE Healthcare, UK). For the CHX assay,
cells were treated with 50 mg/ml CHX (Sigma, UK) for 2 and
4 h prior to lysis. Each experiment was performed at least four
times. Protein quantitation was carried out using ImageJ.
Immunoprecipitation
Protein G magnetic Dynabeads (Invitrogen, UK) were blocked
overnight with 0.2% (w/v) BSA and 0.02% (v/v) tween 20 in
PBS at 48C in an end-over-end rotor. Cells were lysed with 1%
(w/v) DM lysis buffer containing 5% (v/v) mammalian PIC
and 5 mM EDTA in PBS. After lysis, some lysate was kept for
the input fraction and after the addition of 2× SDS buffer was
stored in 2208C. The remaining lysate was separated in differ-
ent IP conditions and incubated for 2 h at room temperature
or overnight at 48C in an end-over-end with the pre-blocked
Dynabeads and with 1–4 mg of specific antibody or 1–4 mg of
non-specific IgG. Following incubation, the bead–antibody–
protein complexes were washed four times with 1% DM
washing buffer. Samples were eluted from the beads with
30 ml of 2× SDS buffer, vortexed for 5 s and spun for 1 min at
12 000×g. Supernatant was collected via the Magnarak to min-
imize magnetic bead contamination. Samples for rod opsin blot
were not denatured, whereas samples for all the other antibodies
were heated at 958C for 5 min prior to SDS–PAGE and western
blot.
Quantitative reverse transcriptase PCR
SK-N-SH cells were seeded at a density of 100 000 cells perwell
and transfectedwith 600 ng/well totalDNAprior to cell lysis and
RNA extraction. The RNeasy Mini Kit (Qiagen, UK) was used
for RNA extraction of cell pellets (105 cells), and cDNA prepar-
ation was performed using QuantiTect Reverse Transcription
Kit (Qiagen). Relative quantification by real-time PCR of
ERdj5 against endogenous b-actin-expression levels was mea-
sured using the following sets of primers: human ERdj5
forward (5′ TGAACTACTTTCGGCAAAGAGA 3′) and
reverse (5′ TTTCAGCTCAGGATCATTTGAA 3′); human
beta-actin forward (5′ CCAACCGCGAGAAGATGA 3′) and
reverse (5′ CCAGAGGCGTACAGGGATAG 3′). The relative
expression between comparable samples in relation to the ex-
pressionof the reference gene andgeneof interestwas calculated
through the formula: 22DDCt.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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